No Licensed Vaccine for HSV-1 Currently Exists
There is currently no FDA-approved or licensed vaccine available for herpes simplex virus type 1 (HSV-1). 1
Current Clinical Reality
The most recent and authoritative guidelines explicitly state that no vaccine is available for HSV 1. This applies to both HSV-1 (primarily causing oral herpes) and HSV-2 (primarily causing genital herpes), though the question specifically asks about HSV-1.
Management Without a Vaccine
Since vaccination is not an option, current management focuses on:
Antiviral prophylaxis for patients with frequent recurrent attacks:
- Acyclovir 400 mg twice daily
- Valacyclovir 500 mg daily
- Famciclovir 250 mg twice daily 1
Screening before immunosuppression: Patients should be asked about HSV infection history before starting immunosuppressive therapy, as reactivation can cause severe complications including encephalitis, meningitis, pneumonia, esophagitis, and colitis 1
Important Clinical Context
Why This Matters
HSV-1 causes significant morbidity through:
- Recurrent oral and genital herpes (more frequent and severe in immunocompromised patients)
- Severe complications even in immunocompetent individuals: keratitis, encephalitis, retinitis 1
- Life-long latent infection with no cure 2
Vaccine Development Status
While no vaccine is currently licensed, multiple vaccine candidates are in development [3-4]. Recent research (2024-2026) shows promising results with:
- Live attenuated vaccines
- mRNA vaccine platforms
- Protein subunit vaccines
However, these remain investigational and are not available for clinical use.
Common Pitfall
Do not confuse HSV vaccines with the varicella-zoster virus (VZV) vaccine, which IS available. VZV causes chickenpox and shingles and is a different herpesvirus. The recombinant zoster vaccine (RZV) is recommended for certain populations, but this does NOT protect against HSV-1 1.